Predictions
Cytosorbents Corp.
Start price
Target price
Perf. (%)
€1.83
17.09.23
17.09.23
-
17.09.24
17.09.24
-52.14%
19.01.24
19.01.24
Probably not worthwhile Investment
Bio-Gate AG
Start price
Target price
Perf. (%)
€1.06
26.12.23
26.12.23
-
26.12.24
26.12.24
-8.96%
11.01.24
11.01.24
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Sernova Corp.
Start price
Target price
Perf. (%)
€0.53
30.12.22
30.12.22
€5.00
30.12.25
30.12.25
-10.84%
15.12.23
15.12.23
Could be very worthwhile Investment >20% year
Fresenius Medical Care AG & Co KGaA ST
Start price
Target price
Perf. (%)
€33.12
11.10.23
11.10.23
-
11.10.24
11.10.24
14.79%
12.12.23
12.12.23
Known brand
Could be worthwhile Investment >10% per year
Tabula Rasa HealthCare Inc
Start price
Target price
Perf. (%)
€9.35
08.08.23
08.08.23
-
08.08.24
08.08.24
5.88%
11.12.23
11.12.23
Probably not worthwhile Investment
Bovie Medical Corp
Start price
Target price
Perf. (%)
€2.34
16.10.23
16.10.23
-
16.10.24
16.10.24
-15.38%
11.12.23
11.12.23
Risky Investment
Community Health Systems Inc.
Start price
Target price
Perf. (%)
€2.00
30.10.23
30.10.23
-
30.10.24
30.10.24
15.00%
11.12.23
11.12.23
Probably not worthwhile Investment
scPharmaceuticals
Start price
Target price
Perf. (%)
€4.66
13.11.23
13.11.23
-
13.11.24
13.11.24
12.66%
11.12.23
11.12.23
Probably not worthwhile Investment
MicroVision Inc
Start price
Target price
Perf. (%)
€2.44
02.12.23
02.12.23
€2.00
02.12.24
02.12.24
-1.29%
05.12.23
05.12.23
Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
MicroVision Inc
Start price
Target price
Perf. (%)
€2.36
29.11.23
29.11.23
€2.00
29.11.24
29.11.24
3.49%
02.12.23
02.12.23
Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
MicroVision Inc
Start price
Target price
Perf. (%)
€2.23
23.11.23
23.11.23
€2.00
23.11.24
23.11.24
5.92%
29.11.23
29.11.23
Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
MicroVision Inc
Start price
Target price
Perf. (%)
€2.11
27.09.23
27.09.23
€4.00
27.09.24
27.09.24
5.76%
23.11.23
23.11.23
Fair valuation
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Crossject S.A.
Start price
Target price
Perf. (%)
€4.04
12.11.22
12.11.22
€4.50
12.11.23
12.11.23
5.82%
13.11.23
13.11.23
Could be worthwhile Investment >10% per year
ShockWave Medical Inc
Start price
Target price
Perf. (%)
€285.40
07.09.22
07.09.22
€400.00
31.12.25
31.12.25
-47.00%
12.11.23
12.11.23
Could be very worthwhile Investment >20% year
Bio-Gate AG
Start price
Target price
Perf. (%)
€0.85
11.11.23
11.11.23
-
11.11.24
11.11.24
-
11.11.23
11.11.23
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Bio-Gate AG
Start price
Target price
Perf. (%)
€0.81
05.11.23
05.11.23
-
05.11.24
05.11.24
15.43%
11.11.23
11.11.23
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Bio-Gate AG
Start price
Target price
Perf. (%)
€1.01
03.09.23
03.09.23
-
03.09.24
03.09.24
-19.80%
05.11.23
05.11.23
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Motus GI Holdings Inc.
Start price
Target price
Perf. (%)
€2.12
24.10.22
24.10.22
€3.00
24.10.23
24.10.23
-73.07%
25.10.23
25.10.23
Could be worthwhile Investment >10% per year
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€1.47
26.09.23
26.09.23
-
26.09.24
26.09.24
-26.87%
15.10.23
15.10.23
Could be very worthwhile Investment >20% year
Fresenius Medical Care AG & Co KGaA ST
Start price
Target price
Perf. (%)
€38.99
04.10.23
04.10.23
€22.00
04.10.24
04.10.24
-16.75%
14.10.23
14.10.23
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation